The efficacy and safety of mirogabalin for neuropathic pain

The efficacy and safety of mirogabalin for neuropathic pain - The efficacy and safety of mirogabalin for neuropathic pain

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036855

Enrollment

100

Registered

2019-06-01

Start date

2019-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuropathic pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: neuropathic apin

Exclusion criteria

Exclusion criteria: can not be self-assessment of pain

Design outcomes

Primary

Measure	Time frame
Visual analogue scale (VAS) is assessed before, and, 1 week, 2 weeks, 1 month, 2 months, 3 months,6 months, 1 year after drug administration	—

Countries

Japan

Contacts

Public ContactHiromi Fujii

Kajiki Hospital Anesthesiology

hiromif@ktd.biglobe.ne.jp086-293-3355

Outcome results